Status:
ACTIVE_NOT_RECRUITING
Artificial Intelligence Supporting CAncer Patients Across Europe - the ASCAPE Project
Lead Sponsor:
Region Örebro County
Collaborating Sponsors:
UBITECH
ATOS
Conditions:
Breast Cancer
Prostate Cancer
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
ASCAPE (Artificial intelligence Supporting CAncer Patients across Europe) is a collaborative research project involving 15 partners from 7 countries, including academic medical centers, SMEs (small an...
Eligibility Criteria
Inclusion
- The patient selection process varies among the different study sites. Three Hospitals (Sismanogleio General Hospital Athens (SGHA), Örebro University Hospital (ÖUH), Uppsala University Hospital (UUH)) will include patients with newly diagnosed breast- (ÖUH, UUH) or prostate cancer (SGHA, ÖUH) who are eligible for curative treatment with surgery (breast cancer in ÖUH and UUH; prostate cancer in NKUA) or radiotherapy (prostate cancer; ÖUH).
- One Hospital (Barcelona) will include breast cancer survivors (at least 12 months after surgery or chemotherapy) with follow-up through the Hospital.
- Finally, CareAcross will include patients with breast- or prostate cancer through its online platform for patients seeking for the CareAcross services.
- Inclusion Criteria (breast cancer; ORB and Uppsala):
- breast cancer diagnosis
- no clinical evidence of metastatic disease
- able for curative treatment with surgery with or without oncological treatment.
- Inclusion Criteria (breast cancer; Barcelona)
- prior early breast cancer who are at follow-up with at least 12 months after surgery or chemotherapy (whichever occurred last).
- Inclusion Criteria (breast cancer; CareAcross)
- breast cancer diagnosis (as per self-reported) irrespective of stage and treatment.
- Inclusion Criteria (prostate cancer; SGHA and ORB)
- proostate cancer diagnosis
- no clinical evidence of metastatic disease
- able for curative treatment with surgery with or without oncological treatment (SGHA) or radiotherapy (with or without prior surgery) irrespectively the type of radiotherapy (external radiotherapy, brachytherapy, or combination).
- Inclusion Criteria (prostate cancer; CareAcross)
- prostate cancer diagnosis (as per self-reported) irrespective of stage and treatment.
- Exclusion Criteria (common in all study sites):
- inability to give informed consent
- inability / no access to smartphones, applications or internet services
- patients with known medical history of allergy to the wearable material.
Exclusion
Key Trial Info
Start Date :
February 1 2021
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
August 30 2025
Estimated Enrollment :
500 Patients enrolled
Trial Details
Trial ID
NCT04879563
Start Date
February 1 2021
End Date
August 30 2025
Last Update
November 19 2024
Active Locations (5)
Enter a location and click search to find clinical trials sorted by distance.
1
Urology Department, Sismanogleio General Hospital
Athens, Greece
2
Oncology Department, Hospital Clínic de Barcelona
Barcelona, Spain
3
Department of Oncology, Örebro University Hospital
Örebro, Sweden
4
Department of Oncology, University Hospital of Uppsala
Uppsala, Sweden